This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included.
Background
Opioid overdose is a global health crisis, affecting over 27 million individuals worldwide, with more than 100,000 drug overdose deaths in the United States in 2022-2023. This protocol outlines the development of the PneumoWave chest biosensor, a wearable device being designed to detect respiratory depression in real time through chest motion measurement, intending to enhance early intervention and thereby reduce fatalities.
Objective
The study aims to (1) differentiate opioid-induced respiratory depression (OIRD) from nonfatal opioid use patterns to develop and refine an overdose detection algorithm and (2) examine participants’ acceptability of the chest biosensor.
Methods
The study adopts an observational design over a 6-month period. The biosensor, a small device, will be worn by consenting participants during injecting events to capture chest motion data. Safe injecting facilities (SIF) in Melbourne, Victoria (site 1), and Sydney, New South Wales (site 2), which are legally sanctioned spaces where individuals can use preobtained illicit drugs under medical supervision. Each site is anticipated to recruit up to 100 participants who inject opioids and attend the SIF. Participants will wear the biosensor during supervised injecting events at both sites. The biosensor will attempt to capture data on an anticipated 40 adverse drug events. The biosensor’s ability to detect OIRD will be compared to the staff-identified events that use standard protocols for managing overdoses. Measurements will include (1) chest wall movement measured by the biosensor, securely streamed to a cloud, and analyzed to refine an overdose detection algorithm and (2) acute events or potential overdose identified by site staff. Acceptability will be measured by a feedback questionnaire as many times as the participant is willing to throughout the study.
Results
As of April 2024, a total of 47 participants have been enrolled and data from 1145 injecting events have already been collected, including 10 overdose events. This consists of 17 females and 30 males with an average age of 45 years. Data analysis is ongoing.
Conclusions
This protocol establishes a foundation for advancing wearable technology in opioid overdose prevention within SIFs. The study will provide chest wall movement data and associated overdose data that will be used to train an algorithm that allows the biosensor to detect an overdose. The study will contribute crucial insights into OIRD, emphasizing the biosensor’s potential step forward in real-time intervention strategies.
International Registered Report Identifier (IRRID)
Worldwide, more than 27 million people have an opioid use disorder and more than 150,000 people die each year from opioid overdose [1,2]. In the United States, in 2022-2023, there are estimated to be more than 100,000 drug overdose deaths [3]. Naloxone is an opioid antagonist and an antidote to opioid overdose. Effective interventions, such as take-home naloxone are available [4,5] but coverage is incomplete and they are not suited to many overdose situations, such as when people may be alone or the onset of their overdose goes unnoticed [6-8]. In such situations, intervention requires detection of the overdose to signal the need for a response.
Recently, technological developments in wireless “wearable” devices have enabled real-world, real-time measurement of physiological functioning and these devices have grown hugely in popularity [9-11]. Devices in relation to overdose could capture a wide range of different parameters but it is important that these are sensitive, accurate, and reliable. Opioids affect the control of breathing and can cause fatal overdoses, usually by respiratory failure. Respiratory depression, referring to the characteristic effect of opioid drugs, is slowed and shallow breathing (or reduced chest movement) which can sometimes lead to changes in levels of blood gasses and a suppression of the usual responses to these changes. This can lead to hypoxia, respiratory failure, and death. However, currently available wearable devices lack the ability to analyze and interpret respiratory depression data in real time and with sufficient accuracy to achieve medical device regulatory clearance. They are also not practical or economically viable for individual use in the community [12]. A chest sensor that reliably detects the overdose breathing signature, in real time, could alert family or friends to help or could directly alert emergency service. This could save lives when fully developed and used in the community.
The PneumoWave chest biosensor is a small device (Figure 1; 40 mm in diameter and 14 mm in height) that sticks onto the chest using a small plastic patch (an [electrocardiographic] ECG sticker). The device measures chest motion, and consequently will be able to detect changes in chest movement. However, to be relevant to the detection of overdoses in the community, research is required on people at high risk of opioid-induced respiratory depression (OIRD) to capture chest motion during an injecting event, where the absence or presence of overdose can be externally verified. This will then be used to develop and refine sensitive and specific OIRD detection algorithms that can interpret chest movement data in real time on a smartphone or tablet without the need for live clinician analysis and interpretation.
Image of PneumoWave chest sensor and location of placement on the body.
Those who inject opioids die at a much higher rate than other drug-using groups [13]. A safe injecting facility (SIF), also known as a medically supervised injecting center or room, drug consumption room, safe consumption room, or overdose prevention center, is a legally sanctioned space where people can bring their own preobtained illegal or illicit drugs, and either inject or inhale them using sterile equipment under the supervision of nurses or other medical professionals. The main objective of a SIF is to improve survival and increase social integration [14]. However, overdoses, while at a lower rate than the general using population, still occur at SIFs [15]. This also provides an important opportunity for study [16].
In this study, as participants wear the biosensor while they are injecting their opioids, the objectives of the study are (1) to capture chest motion data using the PneumoWave biosensor, and staff-measured outcomes as the clinical reference (including clinical identification of an acute event), during instances of opioid injection and potential opioid overdose by attendees at a SIF, to develop and refine the overdose detection algorithm and (2) to examine acceptability to SIF attendees of the chest biosensor.
MethodsEthical Considerations
This paper is based on version 1.1, April 5, 2023, of the study protocol. Ethics was approved by the Alfred Hospital Ethics Committee (92786). This study adheres to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist (Multimedia Appendix 1).
In order to obtain informed consent, the site research personnel will explain the study methodology to the potential participant, the individual will be given time to read the participant information sheet and consider participation, and if they agree to participate, informed consent will be obtained. Study explanation can occur before or after using the SIF, depending on the preference of the client and aligning with the capacity to consent. Study enrollment and first recording injecting events can, therefore, occur on different days.
Data will be recorded pseudo-anonymously (ie, pseudonyms will be used; no personally identifiable information will be stored alongside chest motion data) and streamed to a secure cloud. Participants who consent to take part will be assigned a numerical study ID number that will be linked to subsequent visits that they make to the Medically Supervised Injecting Centre (MSIC) or Medically Supervised Injecting Room (MSIR). All electronic data will be anonymous and stored on secure, password-protected devices or servers, accessible only by approved study personnel. All paper-based consent forms containing participant names will be kept on site at the MSIC or MSIR following completion and will not be removed from the site.
To reimburse participants for their time and inconvenience, participants will be reimbursed Aus $50 (US $33.20) following initial screening and study enrollment. Participants will then receive a weekly reimbursement of Aus $20 (US $13.30) on the basis they have attended the MSIC or MSIR to inject opioids (either alone or in combination with other drugs) while wearing the biosensor device at least once during the week.
Objectives
The objectives of the study are (1) to capture chest motion data using the PneumoWave biosensor, and staff-measured outcomes as the clinical reference (including clinical identification of an acute event), during instances of opioid injection and potential opioid overdose by attendees at a SIF, to develop and refine the overdose detection algorithm and (2) to examine acceptability to SIF attendees of the chest biosensor.
Study Design
This is an observational pilot study. Over 6 months, this study aims to capture approximately 40 overdose events that occur for consenting participants who are wearing the chest sensor during visits to inject at the SIF. Participants who consent to take part will be assigned an anonymous, numerical study ID number that will be linked to subsequent visits that they make to the SIF.
Chest motion data will be collected on the device securely and pseudo-anonymously (ie, pseudonyms will be used; no personally identifiable information will be stored alongside chest motion data) and streamed to a secure cloud. A SIF is designed to respond to a broad spectrum of adverse drug reactions, recognizing that not all incidents may escalate to an opioid overdose (thus any event that is attended to and requires prompting by staff is termed an “acute event”). The data collected here will be used to test and further develop chest wall movement “signatures” to accurately detect an “acute” drug event or potential overdose, as diagnosed by the current clinical observations in the SIFs. Wearing the device will not alter the services participants receive at the SIF and the sites will manage each acute event as per their standard protocols.
PneumoWave Biosensor and Data Collection Platform
The study will use the PneumoWave biosensor and data collection platform, which includes a wearable biosensor that attaches to the press-stud on a supplied and approved ECG electrode. The biosensor can be placed in a number of locations on the chest and diaphragm area and automatically connects to a Data Hub via Bluetooth (Figure 1). In this study, the Hub will be a router-type device or a mobile computing platform (app running on a tablet or phone).
Once consented to and enrolled in the study, participants will be asked to wear the biosensor each time they attend their relevant SIF to take opioids, an unlimited number of times. There will be no predefined number of visits that each participant should adhere to, though reimbursement will be predicated on attendance to the SIF and wearing of the biosensor at least weekly. We will now highlight the inclusion and exclusion criteria applicable to the study.
Eligibility CriteriaInclusion Criteria
Participants will be recruited from the SIFs via advertisement and direct approach by site personnel and must meet the criteria that are (1) be an adult (18 years of age or older), (2) current injecting opioid user (note: participant may be using other substances as well), (3) regular client of the SIF (minimum of 4 visits in the past month), and (4) willingness to wear biosensor device while injecting at the facility.
Exclusion Criteria
The exclusion criteria are (1) inability to provide informed consent, (2) younger than 18 years of age, (3) not currently injecting opioids, (4) skin sensitivity to ECG electrodes, (5) broken skin over the chest area, (6) implanted pacemaker device in situ, and (7) in the clinical opinion of the investigator would not be suitable to participate.
Sample Size
Participants will be recruited via purposive selection—SIF staff will identify individuals who frequently attend the SIF and inject opioids—and via site advertisements, with individuals approaching site research personnel about potential participation.
During a study period of 6 months, we estimate that approximately 100 participants will be recruited at each participating SIF to meet the desired targets of approximately 2000 opioid injecting visits (a total of 4000 visits), leading to approximately 40 recorded acute or overdose events. This is based on an estimated overdose event rate (the proportion of injections that result in an overdose event) to be 1.2%, from previous data from the medically supervised injecting center in Sydney, New South Wales, Australia [15,17]). An estimated 1200 opioid injecting visits occur per month per site, with an estimated 70 unique individuals attending for opioid injecting per month, per site.
Outcome MeasuresOverview
We will initially separate outcome measures into categories of primary outcome measures (chest motion measures and acceptability) and SIF-determined measures. The latter will then be separated into intervention measures and acute event measures.
Primary Outcome Measures
Capture of chest motion of participants includes chest wall measurements via PneumoWave biosensor of people before and after injection of opioids in a SIF, compared by (1) those experiencing hypoxia and meeting defined criteria for an acute or opioid overdose (SIF-determined outcome measure or acute event) and (2) those not experiencing symptoms of hypoxia or acute or opioid overdose (ie, safe injecting event).
SIF-Determined Outcome Measures
The data that will be collected for each opioid injecting event in the SIF are (1) participant study ID, (2) time or date of client presentation to SIF, (3) substances reported by the participant as intended for injecting (confirmation that opioids are being injected), (4) time of opioid use, and (5) any apnea and prompts to breathe.
The outcome data that will be recorded for any intervention by SIF clinical staff (including acute event response) are (1) precise timing of the first clinical indication of acute event, (2) unique ID number of clinician initially assessing the event to be an opioid overdose, and (3) opioid overdose criteria being met (based on-site specific training materials or opioid overdose reference criteria). These are based on the measures that are described next.
The outcome measures that will be collected for each acute event (including prompts), as applicable are (1) response to audio, physical, and painful stimuli; (2) level of consciousness—timepoints as per standard of care, recorded (using Alert Verbal Pain Unresponsive [AVPU] scale—see Multimedia Appendix 2) at intervals indicated by clinical concern; (3) respiratory rate recorded at least every 5 minutes (though in practice, likely more often) after first clinical indication of opioid overdose; (4) heart rate—timepoints as per standard of care; (5) oxygen saturation via pulse oximetry were measured—timepoints as per standard of care, recorded at intervals indicated by clinical concern; (6) administration of oxygen; (7) administration of manual resuscitation or ventilate (bag-valve-mask ventilation); (8) administration of airway adjunct (nasopharyngeal or oropharyngeal airway); (9) administration of naloxone (yes or no); (10) cardiopulmonary resuscitation; and (11) ambulance called.
Acceptability
Acceptability measures incorporate participant feedback or satisfaction survey (see Multimedia Appendix 3). During study participation, each participant will be asked at least once if they wish to provide feedback on their experience of attaching or wearing the biosensor during injecting drug use. Participants may complete the feedback questionnaire more than once to record fluctuating levels of acceptability. For any feedback provided, the site will collate responses and provide them as an anonymized table listing (see Multimedia Appendix 3). There will also be a subset of participants who will be interviewed and surveyed in more depth.
Participant Timeline and Study Visits
The process of the investigation is more clearly understood through an examination of the schedule of events (visits 1 and then subsequent visits).
Baseline ProceduresOverview
After the participant has consented, completion of participant’s basic, baseline (eg, demographics and drug use characteristics) questionnaire will be conducted using a stand-alone data collection tool using an electronic tablet. Each participant’s height and weight will be recorded at the site at baseline and changes in their height and weight will be recorded every 4 weeks.
The following schedule of events will be followed for visit 1 and then visit 2 (until withdrawal or final self-injecting event).
Visit 1 Procedures (Performed by Site Research Personnel)
Initially, research personnel will confirm the injection of opioids (either alone or in combination with other drugs) and then provide instructions on the use and wearing of the biosensor (Table 1). The biosensor will then be issued to the participant and the biosensor number will be recorded with the participant ID number. The researcher will verify that the biosensor has been correctly attached to the chest wall and provide further guidance to the participant, as required.
Visit 1 (baseline and first study–specific self-injecting visit).
Enrollment or baseline
Prior to injecting event
Acute or overdose eventa
Postinjecting event
Early withdrawalb
Informed consentc
✓
Eligibility criteria
✓
Complete baseline questionnaire
✓
Instructions (use of biosensor)
✓
Issue chest sensor
✓
Attach to chest wall
✓
Record of eventd
✓
Adverse events
✓
✓
✓
✓
Return of biosensor
✓
Early withdrawal form
✓
aIf a self-injecting event occurred without the need for intervention the event should be recorded to reference the time of the device was attached and returned and that no interventions were required.
bIf participant withdraws after providing consent and prior to any use of the sensor.
cConsent and eligibility review, performed at a time most suitable to site personnel and participant during their visit (Multimedia Appendix 4).
dEvent start time, event stop time, assessment of event, and event outcome, if an applicable acute event occurs.
Research personnel will record basic information (day or time and drug reported for injection) for each participant’s SIF attendance. Site research personnel will record the time of self-injecting by monitoring participants from a distance and estimating the time of drug injection (this may include multiple injections within a single episode). If this is not possible to record, the site personnel will document that it could not be collected. Site research personnel will also record event interventions for an acute or overdose event (as applicable), including start time, end time, event assessment or level of intervention, clinicians’ unique ID, and overdose criteria. A record of “no acute event” will also be maintained if the self-injecting visit occurred without any requirement for site personnel intervention. Any adverse events will also be recorded and, if necessary, an early withdrawal form will be completed if the participant did not progress to use the biosensor at visit 1 and declined further participation.
Visit 2 to Withdrawal or Final Self-Injecting Visit (Performed by Site Research Personnel)
At visit 2 and subsequent visits until withdrawal or final self-injecting visit, research personnel will verify that the informed consent remains valid for the participant to continue on the study (Table 2). They will also confirm the injection of opioids (either alone or in combination with other drugs) and provide a reminder instruction on the use and wear of the biosensor. They will then issue the biosensor to the participant and record the biosensor number used with the participant ID. They will verify that the biosensor has been attached to the chest wall correctly and provide further guidance to the participant as required.
Visit 2 to final self-injecting visit.
Prior to injecting event
Acute or overdosea,b event
Postinjecting event
Withdrawalc
Verify informed consent remains valid
✓
Instructions (use of sensor; as required)
✓
Issue chest biosensor
✓
Attach to chest wall
✓
Record of eventd
✓
Adverse events
✓
✓
✓
Return of biosensor
✓
User experience survey (during enrollment period, prior to withdrawal, or final self-injecting visit
Withdrawal formc
✓
aIf a self-injecting event occurred without any need for intervention the event should be recorded to reference the time the device was attached and returned and that no interventions were required.
bIf a self-injecting event occurred without the need for intervention the event should be recorded to reference the time of the device was attached and returned and that no interventions were required.
cFor all withdrawals from visit 2 onwards.
dEvent start time, event stop time, assessment of event, and event outcome, if an applicable acute event occurs.
Site research personnel will record basic information (day or time and drug reported for injection) for each participant’s SIF attendance and will record the time of self-injecting by monitoring the participant from a distance and estimating the time of drug injection (may include multiple injections within a single episode). If this is not possible to record, the site personnel will document that it could not be collected. Site research personnel will also record event interventions for an acute or overdose event (as applicable) including start time, end time, event assessment or level of intervention, clinicians’ unique ID, and overdose criteria. A record of “no acute event” will also be maintained if the self-injecting visit occurred without any requirement for site personnel intervention. Any adverse events will also be recorded and, if necessary, a withdrawal form will be completed if the participant did not progress to use the biosensor and declined further participation.
Example Study Schedule
The number of visits and injection events per participant will differ. The following range of frequency of attendees at the SIF may be anticipated—frequent attendee: 2 visits per day, mid-level attendee: 5 visits per week, and low-level attendee: 1 visit per week [15,17].
Data Management
All data will be captured using a dedicated web-based data system accessible only to site research personnel. Following completion of any given data form, data will be uploaded to a secure, password-protected server managed by the sponsor and located in Canada. It will be the Contract Research Organization’s (CRO) responsibility to manage data security. Following project completion, the CRO will lock the data system from further changes and securely transfer data to PneumoWave, where data will be securely stored. Site-specific data sets will also be provided to the SIF. All data will be anonymous, using only study IDs.
PneumoWave Managed Biosensor Data
As soon as the biosensor chest placement has been carried out, chest movement data will commence being captured. Data from the biosensor will be uploaded securely and automatically to a Data Hub stored in a small container, located within the SIF (Figure 2).
The data storage platform (supplied by Galen Data) complies with HIPAA (Health Insurance Portability and Accountability Act) requirements as set forth in the Galen Cloud HIPAA Compliance Matrix (004-0020), General Data Protection Regulation (GDPR) requirements as set forth in the Galen Cloud GDPR Compliance Matrix (004-0021), and California Consumer Privacy Act (CCPA) requirements. Additionally, Galen Cloud deployed on Amazon Web Services (AWS) is Health Information Trust Alliance (HITRUST) certified.
PneumoWave will review both chest movement data stored within the Galen Cloud and study data, including baseline questionnaire, injecting event, acute event, and satisfaction questionnaire data.
Data management flow. CCPA: California Consumer Privacy Act; CRA: Clinical Research Associate; EDC: Electronic Data Capture; GDPR: General Data Protection Regulation; HIPAA: Health Insurance Portability and Accountability Act; HITRUST: Health Information Trust Alliance; OD: overdose.
Early Withdrawal
Participants may request to withdraw from the study at any stage for any reason without prejudice. Participants will need to complete an early withdrawal form. Participants may also request deletion of all study data collected about them up until the point of their withdrawal.
Study Procedure Risks and Benefits
It is understood there may be the occasional loss of a biosensor with the key issue being the potential for a participant to leave the facility prior to removal of the biosensor. While site personnel will aim to minimize this risk, it does remain a factor for device accountability or traceability records. The safety risk relating to a biosensor being taken off-site is assessed to be minimal. Anticipated risks are expected to be very minimal and with a low chance of occurrence. This is a noninterventional, observational study with retrospective analysis of the biosensor data and no protocol-specified procedures impacting the standard of care. Even so, potential study risks include data breaches. However, all electronic data will be anonymous and stored on secure, password-protected devices or servers, and accessible only by approved study personnel. Numerical study IDs will be used in place of participant names. All paper-based consent forms containing participant names will be kept on-site at the SIF following completion and will not be removed from the site. ECG electrodes used in the study are designed to be worn for up to 3 days continuously. The average duration of wear is expected to be less than 1 hour; however, there is a low risk of mild skin irritation.
Given the preliminary, small-scale nature of this research, it is not anticipated that there will be any direct benefits to participants. This work aims to advance the development of future devices that may identify and intervene during opioid overdose; however, such devices may not eventuate for a number of years. The absence of immediate benefit will be outlined to participants during the consent process.
Safety
The capture of safety events will be solely related to adverse device effects (ADE) and will only be captured for an event relating to the use or wearing of the device. All ADEs and serious ADEs will be recorded by site research personnel and will be assessed for severity (mild, moderate, or severe) by the study team.
All ADEs and serious ADEs will be recorded from the time a participant is enrolled until the participant’s last study visit as per the time periods outlined. Participants who have enrolled but then withdrawn prior to wearing the biosensor for the first time will not have adverse events captured. Only unanticipated effects will be captured as reportable ADEs.
AnalysesStatistical Analysis
For the SIF-determined outcome measures (eg, demographic data) and satisfaction survey, descriptive statistics will be reported using means and SD for continuous data. Absolute numbers and percentages will be reported for categorical data. Any statistical software can be used.
Biosensor AnalysesReference Event
Staff-identified events are any event that has required an intervention by staff in the facility. Interventions can range from a simple audio stimulus, up to and including requesting an ambulance to attend. These events include those where overdose may not have occurred, but the response will have been managed in the same way according to the site’s standard operating procedures. These incidences will be recorded as an “acute event.” Where an overdose has been clearly identified using the tools mentioned previously, these incidences will be identified as “overdose event.” The analysis will incorporate both types of “reference” events.
Algorithm Under Test
The PneumoWave Hub receives and transmits biosensor data to a cloud storage facility. The stored data are then processed in the cloud using experimental algorithms for the presence of reduced chest movement events in adults.
The performance of the algorithm under test will be compared to the reference events at the SIF in terms of the AUT’s sensitivity and false alarm rate. If the target numbers for sample size, injecting visits, and acute events are not reached, the analysis will still be possible and feasible.
Results
Funding was granted in July 2023 and dates for data collection are August 2023 to February 2024. As of April 2024, we have enrolled 47 participants, consisting of 17 females and 30 males with an average age of 45 years. Heroin was the preferred drug for most participants (40/47) and then methadone or an opioid agonist treatment (6/47), with the largest proportion injecting 2 to 5 times daily (BD-5D—n=23), and then once daily (14/47). The majority had experienced an overdose in the past (29/47). Among all the participants, a total of 1145 injecting events were recorded while participants wore the sensor, with 10 overdose events being observed. Data analysis of the outcome measures is ongoing.
Discussion
There has been a recent surge of interest in mobile health and wearable devices to treat opioid use disorders [18,19] and specifically to detect and respond to opioid overdoses. However, there is limited research on detecting true overdose (which requires intervention) and the effectiveness of these devices to detect overdose in the community has not yet been adequately evaluated. A chest sensor that reliably detects the overdose breathing signature could alert the emergency services and save lives when fully developed and used in the community.
This observational study aims to capture chest motion data while participants wear a small chest-worn biosensor within medically supervised injecting centers in Australia. The data collected here will be used to test and develop respiratory “signatures” to accurately detect an acute or potential opioid overdose. Testing will allow for the differentiation of patterns that occur following opioid use but do not result in an overdose.
It is anticipated that this study will capture chest motion data from the sensor while participants inject opioids and it is likely that some instances of potential overdose will also be captured by the sensor. It is uncertain how much chest motion data will be corroborated with staff-measured outcomes. It is anticipated that the sensor will be considered positively overall among participants.
The findings of this study will be compared to a previous study of this chest sensor among participants who wear the sensor at home and are on opioid agonist treatment (paper in preparation), as well as other studies on wearable devices that have been examined acceptability and feasibility of varied technologies to combat the overdose crisis [20-25]. The potential effectiveness and acceptability of these studies are varied. Generally, there is limited but expanding research in this area with studies focused on products or technologies that are relatively new or in early development [12]. There is no published work on a remote chest sensor that can reliably detect chest wall movement in the context of an opioid overdose.
The strengths of this study are that it examines the effectiveness of the chest sensor among people who are injecting opioids in a relatively controlled but real drug-using environment. Research within an SIF is a unique opportunity to address external validity as participants will be those who the sensor is eventually intended for.
However, the study is likely to be limited in a few different ways. First, it is likely that participants will be polydrug users and it may not be possible to examine the effect of opioids alone. Additionally, the number of prompt or acute events is likely to be lower than in other drug-using environments as participants will be users who are using in a safe setting that is aimed at reducing harms and mortality around injecting drug use. This may mean the target number of acute events will be negatively impacted. Other potential limitations could include the physical movement of individuals while using the device interfering with the data capture, or data quality. The more the participants, the better the quality of data will be.
Future development of this work will involve conducting a randomized clinical investigation of a medical device to determine its effectiveness in detecting OIRD. It will also be important to test the device in people’s personal environments, for example, in their homes.
SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines.
AVPU (Alert Verbal Pain Unresponsive) scale.
Participant satisfaction survey.
Consent form.
AbbreviationsADE
adverse device effect
AVPU
Alert Verbal Pain Unresponsive
AWS
Amazon Web Services
CCPA
California Consumer Privacy Act
CRO
Contract Research Organization
ECG
electrocardiography
GDPR
General Data Protection Regulation
HIPAA
Health Insurance Portability and Accountability Act
HITRUST
Health Information Trust Alliance
MSIC
Medically Supervised Injecting Centre
MSIR
Medically Supervised Injecting Room
OIRD
opioid-induced respiratory depression
SIF
safe injecting facility
SPIRIT
Standard Protocol Items: Recommendations for Interventional Trials
The study is funded by PneumoWave (who are developing a chest sensor for the detection of opioid-induced respiratory depression and will submit relevant parts of these findings for further approvals of the device). PneumoWave will have the ultimate decision on the submission of the final report to regulatory authorities with close discussions with King’s College London and academic colleagues in other institutions. PneumoWave is the sponsor of the study.
This study design was conceived and proposed by JS, BT, and WL and all authors contributed to the write-up of the protocol.
BT is supported by National Institute for Health & Care Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley National Health Service (NHS) Foundation Trust, King’s College London and part funded by the Maudsley Charity. JS is a clinician and academic who has worked with local, national and international government and nongovernment agencies to develop and test new approaches to tackling addiction and related problems including risk of death from drug overdose. Through his employer (King’s College London), he has worked with pharma and tech companies (including MundiPharma, Camurus, Accord, Catalent, Pneumowave and CMI in the past 3 years) and his employer (King’s College London) has received project grant support and/or honoraria and/or consultancy payments and also device and app supply in order to develop or study potentially improved formulations and devices. JS’s research is supported by the National Institute for Health & Care Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. WL, PD, DOK, MJ, MB, NC, BH, CC, and OM declare no conflicts of interest.
StrangJVolkowNDDegenhardtLHickmanMJohnsonKKoobGFMarshallBDLTyndallMWalshSLOpioid use disorderNat Rev Dis Primers202061310.1038/s41572-019-0137-53191934910.1038/s41572-019-0137-5AhmadFBCisewskiJARossenLMSuttonPProvisional drug overdose death countsNational Center for Health Statistics20242024-08-06https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htmAhmadFBCisewskiJARossenLMSuttonPProvisional drug overdose death countsNational Center for Health Statistics20232024-08-06https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htmMcDonaldRCampbellNDStrangJTwenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids—conception and maturationDrug Alcohol Depend201717817618710.1016/j.drugalcdep.2017.05.00128654870OlsenADwyerRLentonSTake-home naloxone in Australia and beyondDrug Alcohol Rev201837443743910.1111/dar.1270029744978DavidsonPJMcLeanRLKralAHGleghornAAEdlinBRMossARFatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted interventionJ Urban Health200380226127310.1093/jurban/jtg02912791802PMC3456286WojcickiJMDying alone: the sad irrelevance of naloxone in the context of solitary opiate useAddiction2019114357457510.1111/add.1450830461114StamNCGerostamoulosDSmithKPilgrimJLDrummerOHChallenges with take-home naloxone in reducing heroin mortality: a review of fatal heroin overdose cases in Victoria, AustraliaClin Toxicol (Phila)201957532533010.1080/15563650.2018.152931930451007ChuahSHRauschnabelPAKreyNNguyenBRamayahTLadeSWearable technologies: the role of usefulness and visibility in smartwatch adoptionComput Human Behav20166527628410.1016/j.chb.2016.07.047MarcolinoMSOliveiraJAQD'AgostinoMRibeiroALAlkmimMBMNovillo-OrtizDThe impact of mHealth interventions: systematic review of systematic reviewsJMIR Mhealth Uhealth201861e2310.2196/mhealth.887329343463v6i1e23PMC5792697PipekLZNascimentoRFVAcencioMMPTeixeiraLRComparison of SpO2 and heart rate values on Apple watch and conventional commercial oximeters devices in patients with lung diseaseSci Rep20211111890110.1038/s41598-021-98453-33455676510.1038/s41598-021-98453-3PMC8460792TasBLawnWTraykovaEVEvansRASMurvaiBWalkerHStrangJA scoping review of mHealth technologies for opioid overdose prevention, detection and responseDrug Alcohol Rev202342474876410.1111/dar.1364536933892DegenhardtLBucelloCMathersBBrieglebCAliHHickmanMMcLarenJMortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studiesAddiction20111061325110.1111/j.1360-0443.2010.03140.x21054613Drug consumption rooms: an overview of provision and evidenceEMCDDA European Monitoring Centre for Drugs and Drug Addiction20182024-08-06https://www.euda.europa.eu/topics/pods/drug-consumption-rooms_enRoxburghADarkeSSalmonAMDobbinsTJaunceyMFrequency and severity of non-fatal opioid overdoses among clients attending the sydney medically supervised injecting centreDrug Alcohol Depend201717612613210.1016/j.drugalcdep.2017.02.02728535454S0376-8716(17)30205-3DietzePJaunceyMSalmonAMohebbiMLatimerJvan BeekIMcGrathCKerrDEffect of intranasal vs intramuscular naloxone on opioid overdose: a randomized clinical trialJAMA Netw Open2019211e191497710.1001/jamanetworkopen.2019.14977317220242755306PMC6902775SalmonAMDwyerRJaunceyMvan BeekIToppLMaherLInjecting-related injury and disease among clients of a supervised injecting facilityDrug Alcohol Depend20091011-213213610.1016/j.drugalcdep.2008.12.00219167171S0376-8716(08)00433-XNuamahJMehtaRSasangoharFTechnologies for opioid use disorder management: mobile app search and scoping reviewJMIR Mhealth Uhealth202086e1575210.2196/1575232501273v8i6e15752PMC7305558GoldfineCLaiJTLuceyENewcombMCarreiroSWearable and wireless mHealth technologies for substance use disorderCurr Addict Rep20207329130010.1007/s40429-020-00318-833738178PMC7963000NandakumarRGollakotaSSunshineJEOpioid overdose detection using smartphonesSci Transl Med201911474eaau891410.1126/scitranslmed.aau89143062671711/474/eaau8914AhamadKDongHJohnsonCHyashiKDeBeckKMilloyMJWoodEFactors associated with willingness to wear an electronic overdose detection deviceAddict Sci Clin Pract20191412310.1186/s13722-019-0153-53126996310.1186/s13722-019-0153-5PMC6610816TasBWalkerHLawnWMatchamFTraykovaEVEvansRASStrangJWhat impacts the acceptability of wearable devices that detect opioid overdose in people who use opioids? A qualitative studyDrug Alcohol Rev202443121322510.1111/dar.1373737596977KanterKGallagherREwejeFLeeAGordonDLandySGasiorJSoto-CalderonHCronholmPFCocchiaroBWeimerJRothALankenauSBrennerJWillingness to use a wearable device capable of detecting and reversing overdose among people who use opioids in PhiladelphiaHarm Reduct J20211817510.1186/s12954-021-00522-33430124610.1186/s12954-021-00522-3PMC8299455DhowanBLimJMacLeanMDBermanAGKimMKYangQLinnesJLeeCHGoergenCJLeeHSimple minimally-invasive automatic antidote delivery device (A2D2) towards closed-loop reversal of opioid overdoseJ Control Release201930613013710.1016/j.jconrel.2019.05.04131158402S0168-3659(19)30305-0PMC6629496ImtiazMSBandoianCVSantoroTJHypoxia driven opioid targeted automated device for overdose rescueSci Rep20211112451310.1038/s41598-021-04094-x3497281810.1038/s41598-021-04094-xPMC8720093